FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887481574> ?p ?o ?g. }

• W2887481574 endingPage "52" @default.
• W2887481574 startingPage "46" @default.
• W2887481574 abstract "PurposeTo evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtansine when administered in combination with carboplatin to relapsed ovarian cancer patients.MethodsPatients with recurrent, platinum-sensitive epithelial ovarian or fallopian tube cancer were enrolled. Eligibility included a minimum requirement of tumor FRα positivity (≥25% of cells with ≥2+ staining intensity). Patients received escalating doses of mirvetuximab soravtansine and carboplatin on day 1 of a 21-day cycle (once every 3 weeks). Mirvetuximab soravtansine maintenance therapy was permitted, at the investigators discretion, following cessation of carboplatin treatment. Adverse events, tumor response, and progression-free survival (PFS) were determined.ResultsEighteen patients were enrolled and dosed with combination therapy; thirteen continued with mirvetuximab soravtansine maintenance following carboplatin discontinuation. Mirvetuximab soravtansine dosing was escalated from 5 to 6 mg/kg (adjusted ideal body weight) and carboplatin from AUC4 to AUC5. Adverse events were generally mild (≤ grade 2) with nausea, diarrhea, thrombocytopenia, blurred vision, and fatigue being the most common treatment-emergent toxicities. For all evaluable patients (n = 17), the confirmed objective response rate (ORR) was 71%, including three complete responses and nine partial responses, and the median PFS was 15 months. A median duration of response was not reached.ConclusionThese data demonstrate that mirvetuximab soravtansine combined with carboplatin is a well-tolerated and highly active regimen in recurrent, platinum-sensitive ovarian cancer. Further evaluation of this combination in a randomized fashion is warranted." @default.
• W2887481574 created "2018-08-22" @default.
• W2887481574 creator A5007606531 @default.
• W2887481574 creator A5021359849 @default.
• W2887481574 creator A5058535647 @default.
• W2887481574 creator A5069337573 @default.
• W2887481574 creator A5079585064 @default.
• W2887481574 creator A5081561534 @default.
• W2887481574 creator A5089503365 @default.
• W2887481574 date "2018-10-01" @default.
• W2887481574 modified "2023-10-17" @default.
• W2887481574 title "Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer" @default.
• W2887481574 cites W1933854096 @default.
• W2887481574 cites W1976817697 @default.
• W2887481574 cites W2009193838 @default.
• W2887481574 cites W2019607817 @default.
• W2887481574 cites W2024132257 @default.
• W2887481574 cites W2024856950 @default.
• W2887481574 cites W2027110022 @default.
• W2887481574 cites W2030177226 @default.
• W2887481574 cites W2049490668 @default.
• W2887481574 cites W2062426114 @default.
• W2887481574 cites W2064435613 @default.
• W2887481574 cites W2069885515 @default.
• W2887481574 cites W2104182248 @default.
• W2887481574 cites W2104998982 @default.
• W2887481574 cites W2120350077 @default.
• W2887481574 cites W2122624385 @default.
• W2887481574 cites W2129949847 @default.
• W2887481574 cites W2132526578 @default.
• W2887481574 cites W2133894270 @default.
• W2887481574 cites W2138035969 @default.
• W2887481574 cites W2139761471 @default.
• W2887481574 cites W2151050516 @default.
• W2887481574 cites W2160466424 @default.
• W2887481574 cites W2162318396 @default.
• W2887481574 cites W2165168809 @default.
• W2887481574 cites W2171658624 @default.
• W2887481574 cites W2202939373 @default.
• W2887481574 cites W2329492928 @default.
• W2887481574 cites W2528228811 @default.
• W2887481574 cites W2549573446 @default.
• W2887481574 cites W2567395185 @default.
• W2887481574 cites W2605456582 @default.
• W2887481574 cites W2608845032 @default.
• W2887481574 cites W2745539538 @default.
• W2887481574 cites W2754327139 @default.
• W2887481574 cites W2766002634 @default.
• W2887481574 cites W2771290640 @default.
• W2887481574 cites W2772815803 @default.
• W2887481574 cites W2789851018 @default.
• W2887481574 cites W2544058517 @default.
• W2887481574 doi "https://doi.org/10.1016/j.ygyno.2018.07.017" @default.
• W2887481574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30093227" @default.
• W2887481574 hasPublicationYear "2018" @default.
• W2887481574 type Work @default.
• W2887481574 sameAs 2887481574 @default.
• W2887481574 citedByCount "39" @default.
• W2887481574 countsByYear W28874815742018 @default.
• W2887481574 countsByYear W28874815742019 @default.
• W2887481574 countsByYear W28874815742020 @default.
• W2887481574 countsByYear W28874815742021 @default.
• W2887481574 countsByYear W28874815742022 @default.
• W2887481574 countsByYear W28874815742023 @default.
• W2887481574 crossrefType "journal-article" @default.
• W2887481574 hasAuthorship W2887481574A5007606531 @default.
• W2887481574 hasAuthorship W2887481574A5021359849 @default.
• W2887481574 hasAuthorship W2887481574A5058535647 @default.
• W2887481574 hasAuthorship W2887481574A5069337573 @default.
• W2887481574 hasAuthorship W2887481574A5079585064 @default.
• W2887481574 hasAuthorship W2887481574A5081561534 @default.
• W2887481574 hasAuthorship W2887481574A5089503365 @default.
• W2887481574 hasBestOaLocation W28874815741 @default.
• W2887481574 hasConcept C121608353 @default.
• W2887481574 hasConcept C126322002 @default.
• W2887481574 hasConcept C126894567 @default.
• W2887481574 hasConcept C141071460 @default.
• W2887481574 hasConcept C143998085 @default.
• W2887481574 hasConcept C197934379 @default.
• W2887481574 hasConcept C2776694085 @default.
• W2887481574 hasConcept C2778239845 @default.
• W2887481574 hasConcept C2778715236 @default.
• W2887481574 hasConcept C2780427987 @default.
• W2887481574 hasConcept C2780580376 @default.
• W2887481574 hasConcept C2781413609 @default.
• W2887481574 hasConcept C2781451048 @default.
• W2887481574 hasConcept C31760486 @default.
• W2887481574 hasConcept C71924100 @default.
• W2887481574 hasConcept C90924648 @default.
• W2887481574 hasConceptScore W2887481574C121608353 @default.
• W2887481574 hasConceptScore W2887481574C126322002 @default.
• W2887481574 hasConceptScore W2887481574C126894567 @default.
• W2887481574 hasConceptScore W2887481574C141071460 @default.
• W2887481574 hasConceptScore W2887481574C143998085 @default.
• W2887481574 hasConceptScore W2887481574C197934379 @default.
• W2887481574 hasConceptScore W2887481574C2776694085 @default.
• W2887481574 hasConceptScore W2887481574C2778239845 @default.
• W2887481574 hasConceptScore W2887481574C2778715236 @default.

• next